TL;DR
The Buck Institute and Georgetown University are co-leading a four-year research effort backed by an ARPA-H award of up to $51.7 million. The SEEDS consortium will combine experiments and computational models to study how intrinsically disordered proteins change under different cellular conditions, with initial work focused on Alzheimer’s disease and Ewing sarcoma.
The Buck Institute for Research on Aging and Georgetown University will co-lead a four-year research project, backed by an award of up to $51.7 million from the Advanced Research Projects Agency for Health, to predict how certain flexible proteins change before they contribute to disease. The consortium plans to combine computational modeling with laboratory experiments, initially studying proteins linked to Alzheimer’s disease and Ewing sarcoma.
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The consortium, called SEEDS—Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale—will study intrinsically disordered proteins, or IDPs. Unlike proteins that usually settle into a relatively stable three-dimensional shape, IDPs can take on many forms. Their behavior can shift in response to conditions inside cells, including acidity, molecular crowding, metals, metabolites and chemical modifications.
The team aims to develop a platform that predicts protein behavior using both a protein’s sequence and its surroundings. It will test computational predictions against experimental measurements, rather than relying on models alone. The stated aim is to identify changes associated with disease early enough to inform future diagnostics and possible ways to slow or redirect those changes.
SEEDS brings together researchers from nine academic institutions and seven industry partners. It combines two groups, Georgetown’s INTREPID and the Buck Institute’s SHIFT, with expertise spanning protein science, artificial intelligence, computational modeling, cancer and neuroscience. The project is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention, or BIOGAMI, program.
Why Early Protein Changes Matter
The project focuses on a stage that can be difficult to observe: changes in flexible proteins before they form aggregates or cause lasting cellular damage. Protein misfolding and aggregation are associated with Alzheimer’s disease, amyotrophic lateral sclerosis and some cancers, among other chronic and degenerative conditions. A better account of when and why these proteins change could give researchers a basis for investigating earlier detection or intervention.
Many proteins implicated in these processes have been described as hard to target with conventional drugs. They may lack the stable shapes and binding pockets that many drug-development approaches are built around. If the consortium can predict how an IDP’s behavior shifts with its cellular environment, that knowledge could eventually help researchers identify new diagnostic or therapeutic strategies. The award supports research toward those possibilities; it does not establish that a new test or treatment will result.
Popular right now
Dyson Ball Animal 3 Upright Corded Vacuum
Bose QuietComfort True Wireless Earbuds with Active Noise Cancellation, Bluetooth 5.3, USB-C Charging, IPX4, Black
Dyson V8 Motorhead Origin Cordless Vacuum
As an affiliate, we earn on qualifying purchases.
The Challenge of Flexible Proteins
Researchers can capture snapshots of some proteins, often after they have already clumped together, but the source report says they cannot yet reliably predict how IDPs will behave as cellular conditions change or when a shift becomes harmful. Their flexibility is useful in healthy cells, where these proteins carry out important functions, but it also complicates efforts to describe and target them.
Protein-prediction tools such as AlphaFold have drawn on decades of accumulated structural data. SEEDS researchers say comparable information is lacking for intrinsically disordered proteins, making their behavior harder to model. The consortium plans to collect and analyze data at scale while studying selected proteins closely enough to test how context alters their behavior.
The BIOGAMI program frames this goal as learning a molecular “grammar”: rules connecting protein sequence and environment to protein behavior. BIOGAMI is led by ARPA-H Program Manager Shannon Greene. The SEEDS project is one effort within that program focused on the early stages of protein dysfunction.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
What the Project Has Yet to Show
The award launches a research effort; it does not mean the team can already predict harmful changes reliably or prevent disease. The source report does not specify how much of the up to $51.7 million will ultimately be paid, nor does it provide detailed project milestones, a breakdown of funding among participants or a timeline for public results.
It is also unclear which specific proteins beyond the initial focus areas will be studied, what performance standards the models must meet, and whether any resulting approach will be suitable for clinical use. The proposed applications in diagnostics and treatment remain goals, and findings will need experimental validation and further research.
Testing Predictions Against Experiments
Over the project’s four-year period, SEEDS researchers plan to map protein behavior across different cellular conditions, build computational predictions and compare those predictions with experimental measurements. That feedback is intended to refine the models and clarify how sequence and environment jointly shape the behavior of IDPs.
The next meaningful developments will be the team’s experimental results, evidence about how well its predictions hold up, and any reported progress toward identifying early changes relevant to Alzheimer’s disease or Ewing sarcoma. The source announcement does not give dates for those updates. Any diagnostic or treatment applications would require additional development and validation beyond the modeling work described.
Key Questions
What is the SEEDS project?
SEEDS is a research consortium co-led by the Buck Institute and Georgetown University. It will study how intrinsically disordered proteins behave under different conditions inside cells, using computational models and experiments.
How much funding did the project receive?
ARPA-H awarded the effort up to $51.7 million for a four-year project. The announcement does not state how much will ultimately be paid or how the award will be divided among partners.
Which diseases will the researchers initially study?
The project’s initial focus is on Alzheimer’s disease and Ewing sarcoma. The announcement describes these as starting areas, not the only conditions the research could address.
Does the award mean a new diagnostic or treatment is available?
No. The project aims to generate knowledge that could support future diagnostics or treatments. The announcement reports a research effort, not a validated test, approved therapy or demonstrated way to prevent disease.
Source: rss
